Cannabinoids as Anti-Cancer Agents, with Prof. Guillermo Velasco PhD

Cannabinoids as Anti-Cancer Agents, with Prof. Guillermo Velasco PhD

Cannabinoids as Anti-Cancer Agents, with Prof. Guillermo Velasco PhD. We spoke with Prof. Guillermo Velasco Ph.D. from the Department of Biochemistry and Molecular Biology at the University of Madrid, Spain at the IACM Cannabinoids in Medicine conference 2019 in Berlin, Germany. Prof. Velasco outlined the promising pre-clinical and clinical evidence supporting the use of cannabinoids to kill several different types of cancers through autophagy (self-cleaning of cells) and eventual apoptosis (programmed cell death).

Cannabinoids as Anti-Cancer Agents

Innovation and Technology transfer scientist with a background in European Commission research projects and wide experience in lecturing at first-class High Education institutions. Expert in Innovation management, Technology transfer, Strategic intelligence, IPR, and Future trends analysis. Doctorate Ph.D. award focused on Foresight and Innovation Policies from the University of Manchester. Guillermo Velasco was born in Madrid, studied Biology and obtained his Ph.D. degree (1997) at the School of Biology of the Complutense University, Madrid, Spain. After defending his Ph.D., he got an EMBO long-term fellowship to work in Philip Cohen’s laboratory at the MRC Protein Phosphorylation Unit (Dundee, Scotland, UK). Since the year 2003, he is an Associated Professor of the Department of Biochemistry and Molecular Biology I at Complutense University. On the year 2001, he started a line of research aimed at investigating the mechanisms underlying cannabinoid antitumoral action as well as at optimizing the potential clinical utility of these agents in cancer therapies. Guillermo has published more than 70 articles and reviews in international journals, many of them in relation to the anticancer activity of cannabinoids.

IACM Conference on Cannabinoids in Medicine aims to advance knowledge on cannabis, cannabinoids, the endocannabinoid system, and related topics especially with regard to their therapeutic potential. It supports research into cannabis products and the endocannabinoid system, and promotion of exchange of information between researchers, health care practitioners, patients, and the public.